new England journal of medicine

A Family Legacy: Improving Global Public Health


When Dr. Charles A. Knirsch, MD, MPH, joined Pfizer more than 20 years ago, planning had just begun for a new partnership to eliminate trachoma, a neglected tropical disease and the world’s leading infectious cause of blindness.

An Intervention That Can Significantly Improve Child Health


The New England Journal of Medicine has published results from a new study showing that the use of an antibiotic significantly reduced mortality among children living in three low-income countries in Sub-Saharan Africa.

Novel Novartis Compound Shows Potential as Effective Therapy for Treating Drug Resistant Malaria

Results published in the New England Journal of Medicine
Press Release
  • Results published in the New England Journal of Medicine demonstrate that
    KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites

  • KAF156, currently in phase IIb, is the first compound from a novel class of antimalarials known as imidazolopiperazines

CVS Health Research Institute Study Finds Smoking Cessation Programs with Financial Incentives Increase Rates of Quitting and Staying Smoke-free

Press Release

WOONSOCKET, R.I., May 13, 2015 /3BL Media/ -- A new study by the CVS Health (NYSE: CVS) Research Institute and researchers at the Perelman School of Medicine at the University of Pennsylvania, published today in the New England Journal of Medicine, finds that employer-sponsored smoking cessation programs with financial incentives are associated with higher rates of quitting smoking and sustained abstinence.

CVS Caremark Uses Data to Combat National Prescription Drug Abuse Epidemic; Program Details Published in New England Journal of Medicine Online

Pharmacy Innovator Urges Greater Transparency in Controlled Substance Prescribing
Press Release

WOONSOCKET, R.I., Aug. 22, 2013 /3BL Media/ --As part of its continuing efforts to combat the national prescription drug abuse epidemic, CVS Caremark (NYSE: CVS) is tapping its extensive database to identify and halt inappropriate prescribing of high risk drugs such as opioid painkillers. By evaluating data on prescriptions filled at CVS/pharmacy, CVS Caremark identified providers with extreme patterns of prescribing such high-risk drugs and suspended controlled substance dispensing for those who could not justify their prescribing habits.

Subscribe to new England journal of medicine